View Clinical Trial (Medical Research Study)
A Phase 1 Study of Brentuximab Vedotin Combined With ABVD for Hodgkin Lymphoma - NCT01060904-77030(Clinical Trial 560839)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Houston |
|
State:
|
|
TX |
| Zip Code: |
|
77030 |
| Conditions: |
|
Disease, Hodgkin |
| Purpose: |
|
The purpose of this study is to assess the safety profile of brentuximab vedotin in
combination with ABVD in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a
phase 1, single-arm, open-label dose escalation study designed to define the MTD, PK,
immunogenicity and anti-tumor activity of brentuximab vedotin in combination with frontline
therapy.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Treatment-naive Hodgkin lymphoma, Stage IIa or IIb-IV
- Measurable disease of at least 1.5 cm
- ECOG performance status <3
Exclusion Criteria:
- History of another primary malignancy that has not been in remission for at least 3
years
- Known cerebral/meningeal disease |
|
|
|
| Study is available at: |
|
MD Anderson Cancer Center / University of Texas
Houston, TX 77030
United States
Primary Contact:
Amanda Copeland
Email: arcopeland@mdanderson.org
Phone: 713-792-9455
Secondary Contact:
Terri Lowe
Email: clinicaltrials@seagen.com
Phone: 866-333-7436 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|